Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 5, 2014, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.00 to $472,150,000.00.

Highlighted Stocks Traded by Insiders:

CBRE Group (CBG) - FREE Research Report

Kirk J. Christopher, who is EVP, Chief Admin. Officer at CBRE Group, sold 16,000 shares at $32.31 on Nov. 5, 2014. Following this transaction, the EVP, Chief Admin. Officer owned 141,389 shares meaning that the stake was reduced by 10.17% with the 16,000-share transaction.

The shares most recently traded at $32.04, down $0.27, or 0.83% since the insider transaction. Historical insider transactions for CBRE Group go as follows:

  • 4-Week # shares sold: 36,358
  • 12-Week # shares sold: 36,358
  • 24-Week # shares sold: 56,358

The average volume for CBRE Group has been 1.7 million shares per day over the past 30 days. CBRE Group has a market cap of $10.7 billion and is part of the financial sector and real estate industry. Shares are up 21.98% year-to-date as of the close of trading on Wednesday.

CBRE Group, Inc. operates as a commercial real estate services and investment company worldwide. The company operates through Americas; Europe, Middle East and Africa; Asia Pacific; Global Investment Management; and Development Services segments. The company has a P/E ratio of 27.3. Currently, there are 4 analysts who rate CBRE Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBG - FREE

TheStreet Quant Ratings rates CBRE Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, growth in earnings per share, increase in net income and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full CBRE Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regulus Therapeutics (RGLS) - FREE Research Report

Isis Pharmaceuticals Inc, who is 10% Owner at Regulus Therapeutics, sold 1.3 million shares at $15.94 on Nov. 5, 2014. Following this transaction, the 10% Owner owned 5.5 million shares meaning that the stake was reduced by 18.83% with the 1.3 million-share transaction.

The shares most recently traded at $19.75, up $3.81, or 19.3% since the insider transaction. Historical insider transactions for Regulus Therapeutics go as follows:

  • 4-Week # shares sold: 250,368
  • 12-Week # shares sold: 393,368
  • 24-Week # shares sold: 507,568

The average volume for Regulus Therapeutics has been 1.2 million shares per day over the past 30 days. Regulus Therapeutics has a market cap of $878.7 million and is part of the health care sector and drugs industry. Shares are up 156.83% year-to-date as of the close of trading on Wednesday.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. Currently, there are 3 analysts who rate Regulus Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RGLS - FREE

TheStreet Quant Ratings rates Regulus Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow. Get the full Regulus Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Westinghouse Air Brake Technologies (WAB) - FREE Research Report

Kovac Charles F, who is Senior Vice President, Freight at Westinghouse Air Brake Technologies, sold 12,000 shares at $86.84 on Nov. 5, 2014. Following this transaction, the Senior Vice President, Freight owned 114,981 shares meaning that the stake was reduced by 9.45% with the 12,000-share transaction.

The shares most recently traded at $87.36, up $0.52, or 0.6% since the insider transaction. Historical insider transactions for Westinghouse Air Brake Technologies go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 11,000

The average volume for Westinghouse Air Brake Technologies has been 570,500 shares per day over the past 30 days. Westinghouse Air Brake Technologies has a market cap of $8.2 billion and is part of the services sector and transportation industry. Shares are up 16.35% year-to-date as of the close of trading on Wednesday.

Westinghouse Air Brake Technologies Corporation, doing business as Wabtec Corporation, provides technology-based products and services for the freight rail and passenger transit industries worldwide. It operates in two segments, Freight and Transit. The stock currently has a dividend yield of 0.28%. The company has a P/E ratio of 24.8. Currently, there are 4 analysts who rate Westinghouse Air Brake Technologies a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WAB - FREE

TheStreet Quant Ratings rates Westinghouse Air Brake Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Westinghouse Air Brake Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists